New Startup Pledges to Develop Drug to Fight Pituitary Tumors

Written on .

A new pharmaceutical startup called Tiberio has just launched with $31 million in funding- with the stated goal of developing drugs that target pituitary tumors. The company has licensed two compounds from Ipsen Pharmaceuticals and plans to do additional research. One compound, TBR-760 previously failed in tests to combat acromegaly but Tiberio believes it shows promise for shrinking other types of pituitary tumors. Read more here: https://www.bizjournals.com/boston/news/2019/01/03/cambridge-drug-developer-tiburio-launches.html

Print